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Abstract
Immunotherapy approaches stand out as innovative strategies to eradicate tumor cells.
Among them, PD-1/PD-L1 immunotherapy is considered one of the most successful
advances in the history of cancer immunotherapy. We used our technology of Polypurine
reverse Hoogsteen hairpins (PPRHs) for silencing both genes with the aim to provoke the
elimination of tumor cells by macrophages in co-culture experiments. Incubation of PPRHs
against PD-1 and PD-L1 decreased the levels of mRNA and protein in THP-1 monocytes
and PC3 prostate cancer cells, respectively. Viability of THP-1 cells and macrophages
obtained by PMA-differentiation of THP-1 cells was not affected upon incubation with the dif-
ferent PPRHs. On the other hand, PC3 cell survival was partially decreased by PPRHs
against PD-L1. The greatest effect in decreasing cell viability was obtained in macrophages/
PC3 co-culture experiments by combining PPRHs against PD-1 and PD-L1. This effect was
also observed in other cancer cell lines: HeLa, SKBR3 and to a minor extent in M21. Apopto-
sis was not detected when macrophages were treated with the different PPRHs. However,
co-cultures of macrophages with the four cancer cell lines treated with PPRHs showed an
increase in apoptosis. The order of fold-increase in apoptosis was HeLa > PC3 > SKBR3 >
M21. This study demonstrates that PPRHs could be powerful pharmacological agents to
use in immunotherapy approaches for the inhibition of PD-1 and PD-L1.
Introduction
It is well known that the immune system can prevent the formation and progression of tumors
by (i) eliminating viral infections that could lead to tumor formation, (ii) solving inflammation
processes to avoid tumorigenesis and (iii) identifying and eliminating tumor cells depending
on the expression of tumor-specific antigens (immune surveillance). Macrophages are one of
the most important components involved in tumor elimination within the immune surveil-
lance process [1,2]. Although macrophage cytotoxicity in tumors can be achieved by cytokine
secretion, phagocytosis is the main process involved in tumor clearance [3,4]. One of the
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mechanisms of macrophages to trigger phagocytosis against tumor cells but avoiding normal
tissues relies on distinguishing between non-self-molecules from self-molecules. When macro-
phages do not recognize tumor cells, these are not eliminated by the immune system, which
represents one of the hallmarks of cancer [5].
During the last decade, immunotherapy approaches arose as innovative strategies to eradi-
cate tumor cells. There is a wide spectrum of available immunotherapies ranging from cyto-
kines such as IL-2 and IFN-α [6], cell-based therapies like vaccines [7] or adoptive cellular
therapy to stimulate host’s immune system [8–11], and immune checkpoint blockade strate-
gies using anti-CTLA-4 [12] or anti-PD-1 and anti-PD-L1 antibodies to trigger new immune
responses against the tumor. Among them, PD-1/PD-L1 pathway has been the focus of exten-
sive research in the recent years and it is considered one of the most successful advances in the
history of cancer immunotherapy [12–14].
Programmed cell death protein 1 (PD-1) is an immunoinhibitory receptor that belongs to
the CD28 family and it is expressed on B cells, activated T cells, dendritic cells, natural killer
cells, tumor-infiltrating lymphocytes and activated monocytes. PD-1 has two main ligands:
programmed cell death-ligand 1 (PD-L1) and programmed cell death-ligand 2 (PD-L2)
[15,16]. However, research is more focused on PD-L1 because of its overexpression in different
types of tumors [17,18].
In the tumor microenvironment, it is well established that PD-1 and its ligand PD-L1 are
important in tumor progression and survival by escaping tumor neutralizing immune surveil-
lance. Gordon et al. demonstrated that, by blocking PD-1/PD-L1 interaction with antibodies,
the phagocytic potency of macrophages increased in vivo, thus reducing tumor growth in a
cancer mouse model [19]. Giving the importance of PD-1/PD-L1 interaction to avoid phago-
cytosis, we used Polypurine reverse Hoogsteen hairpins (PPRHs) to silence both genes with
the aim to provoke the elimination of tumor cells by macrophages.
PPRHs are non-modified single-stranded deoxyoligonucleotides formed by two antiparallel
polypurine stretches linked by a pentathymidine loop. The intramolecular linkage consists of
reverse Hoogsteen bonds that are formed between guanines and adenines, originating the
hairpin structure. PPRHs can bind to polypyrimidine domains in the double-stranded DNA
(dsDNA) via Watson-Crick bonds, thus displacing the fourth strand of the dsDNA and pro-
ducing a triplex structure. That conformation leads to a transcriptional disruption that pro-
vokes the gene silencing effect [20,21]. Therefore, it is essential for PPRH design to find
polypyrimidine tracts within the target gene sequence, which are mainly present in promoter
or intronic regions [22].
In a previous study, we used this technology to conduct an immunotherapy approach based
on silencing the SIRPα gene in macrophages and the CD47 gene in breast cancer MCF-7 cells,
to avoid their interaction and provoke the elimination of tumor cells by macrophages in co-
culture experiments [23]. In addition, we demonstrated that PPRHs can act as pharmacologi-
cal agents without causing hepatotoxicity or nephrotoxicity [24].
The aim of the present study was to eliminate tumor cells by macrophages in co-culture
experiments by decreasing both the levels of PD-1 in macrophages and those of PD-L1 in dif-
ferent cancer cells using PPRHs and to evaluate the involvement of apoptosis in this approach.
Materials and methods
Cell culture and PMA induced differentiation
Prostate cancer PC3, melanoma M21, ovarian cancer HeLa, breast cancer SKBR3, and mono-
cyte THP-1 cell lines were grown in Ham´s F-12 medium supplemented with 10% fetal bovine
serum (both from Gibco, Barcelona, Spain) at 37˚C in a 5% CO2-controlled humidified
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atmosphere. Trypsinization of cancer cells was performed using 0.05% Trypsin in PBS 1X (154
mM NaCl, 3.88 mM H2NaPO4 and 6.1 mM HNaPO4 pH 7.4) (Sigma-Aldrich, Madrid, Spain).
THP-1 monocytes grew on suspension.
THP-1 cells were incubated with 2 ng/mL phorbol12-myristate 13-acetate (PMA) (Sigma-
Aldrich, Madrid, Spain) for differentiation into macrophages. This concentration was chosen
due to the patterns of pro-inflammatory cytokines and surface marker levels observed after
three days of differentiation [23]. We routinely checked THP-1 differentiation by monitoring
their adhesion to the plate and changes in cell morphology.
Design of PPRHs
PPRHs were designed using The Triplex Oligonucleotide Target Sequence Search Software
(http://utw10685.utweb.utexas.edu/tfo/, Austin, Texas, USA).
PPRHs were synthesized as non-modified desalted oligodeoxynucleotides by Sigma-
Aldrich (HaverHill, United Kingdom). Lyophilized PPRHs were resuspended in sterile Tris-
EDTA buffer (1 mM EDTA and 10 mM Tris, pH 8.0) (Sigma-Aldrich, Madrid, Spain) and
stored at −20˚C until use.
As a negative control, we used a Watson-Crick hairpin (Hp-WC) that forms intramolecular
Watson–Crick bonds instead of reverse Hoogsteen bonds, and therefore the polypurine
domain of the hairpin cannot bind to the polypyrimidine target sequence in the DNA.
The sequences of the PPRHs and the negative control hairpin and their abbreviations are
described in Fig 1.
Transfection of PPRHs
Cells were plated in 6-well dishes. Transfection consisted in mixing 100 nM of PPRH with
10 μM of the cationic liposome N-[1-(2,3-dioleoyloxy)propil]-N,N,N-trimethylammonium
methylsufate (DOTAP) (Biontex, München, Germany) in a final volume of 200 μL of culture
medium. The mixture was incubated for 20 min at room temperature. Finally, the PPRH/
liposome complex was added to the cells to attain a final volume of 1 mL.
RNA extraction
Total RNA was extracted from PC3 and THP-1 cells 24 h and 48 h after transfection, respec-
tively, using TRIzol (Life Technologies, Barcelona, Spain) following the manufacturer’s specifi-
cations. RNA was quantified by measuring its absorbance at 260 nm using a NanoDrop ND-
1000 spectrophotometer (Thermo Fisher Scientific, Barcelona, Spain).
Reverse transcription
cDNA was synthesized by reverse transcription in a 20 μl reaction mixture containing 1 μg of
total RNA, 125 ng of random hexamers (Roche, Madrid, Spain), 500 μM of each dNTP (Pan-
reac Applichem, Barcelona, Spain), 2 μL of 10X buffer, 20 units of RNAse inhibitor and 200
units of Moloney murine leukemia virus reverse transcriptase (Last three from Lucigen, Wis-
consin, USA). The reaction was incubated at 42˚C for 1 h.
Real-time PCR
The StepOnePlus Real-Time PCR Systems (Applied Biosystems, Barcelona, Spain) was used to
perform these experiments. The primer sequences to determine PD1 mRNA levels were
5’GGATTTCCAGTGGCGAGAGA3’ and 5’CAGACGGAGTATGCCACCATT3’. TATA
box binding protein (TBP) was used as endogenous control and the primer sequences were
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5’GAGCTGTGATGTGAAGTTTCC3’ and 5’TCTGGGTTTGATCATTCTGTAG3’. The reac-
tion was performed in a final volume of 20 μl, containing 1 X SYBR Universal PCR Master mix
(Applied Biosystems, Barcelona, Spain), 0.25 μM of reverse and forward primers (Sigma-
Aldrich, Madrid, Spain), 5 μl of cDNA and H2O mQ. PCR cycling conditions were 10 min
denaturation at 95˚C, 40 cycles of 15 s at 95˚C and 1 min at 64˚C.
To determine PD-L1 mRNA levels in PC3 cells, PD-L1 Taqman probe (Assay ID:
Hs00204257_m1) was used. Cyclophilin A Taqman probe (PPIA) (Assay ID: Hs04194521-s1)
was used as endogenous control. The reaction contained 1x TaqMan Universal PCR Master
mix, 1x TaqMan probe (both from Applied Biosystems, Barcelona, Spain), 3 μL of cDNA and
H2O mQ to a final volume of 20 μL. PCR cycling conditions were 10 min denaturation at
95˚C, followed by 40 cycles of 15 s at 95˚C and 1 min at 60˚C.
The mRNA quantification was performed using the ΔΔCt method, where Ct is the thresh-
old cycle that corresponds to the cycle where the amount of amplified mRNA reaches the
Fig 1. PPRHs designed against PD-1 and PD-L1 genes, as well as the negative control hairpin. Abbreviations are (i) Hp, hairpin;
(ii) I, intron; (iii) Pr, promoter; (iv) E, exon. WC stands for the Watson-Crick negative control.
https://doi.org/10.1371/journal.pone.0206818.g001
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threshold of fluorescence. Data were expressed as mRNA levels relative to the cells treated with
the negative control Hp-WC.
Western blot analyses
Total protein extracts from PC3 cells (90,000) were obtained 24 h after transfection. Cells were
washed once with PBS 1X and collected by scrapping in 100 μL of Lysis buffer [150 mM NaCl,
1 mM EDTA, 50 mM Tris-HCl pH 8.0, 1.0% Igepal CA-630 (NP-40), 0.5% sodium deoxycho-
late, 0.1% sodium docecyl sulfate, 1 mM PMSF, 10 mM NAF and Protease inhibitor cocktail
(all from Sigma Aldrich, Madrid, Spain)]. Cell debris was removed by centrifugation (12,000 x
g at 4˚C for 10 min).
In the case of THP-1 monocytes (90,000), cells were collected 48 h after transfection and
centrifuged for 5 min at 800 x g at room temperature. Then, cells were resuspended in 50 μL of
RIPA buffer [150 mM NaCl, 5 mM EDTA, 50 mM Tris-HCl pH 7,4, 1.0% Igepal CA-630 (NP-
40), 100 μg/mL PMSF and Protease inhibitor cocktail (all from Sigma Aldrich, Madrid,
Spain)]. Cell lysate was kept on ice for 30 min, vortexing every 10 min. Cell debris was
removed by centrifugation at 12,000 x g at 4˚C for 10 min. The Bradford method was used to
determine protein concentration using bovine serum albumin as a standard.
Whole cell extracts were resolved in 10% SDS-polyacrylamide gels and transferred to PVDF
membranes. The blocking solution was 5% Blotto. Membranes were probed during 90 min at
room temperature with primary antibodies against PD-L1 (1:250 dilution; PA5-28115,
Thermo Fisher Scientific, Barcelona, Spain), PD-1 (Pdcd-1L1, 1C10; 1:50 dilution; sc-293425,
Santa Cruz Biotechnology, Heidelberg, Germany) and GAPDH (1:200 dilution; sc-47724,
Santa Cruz Biotechnology, Heidelberg, Germany) to normalize the results. Detection was
achieved by secondary HRP-conjugated antibodies: anti-rabbit (1:1000 dilution; Dako, Denk-
mark) for PD-L1 and anti-mouse (1:1000; sc-516102, Santa Cruz Biotechnology, Heidelberg,
Germany) for PD-1 and GAPDH. Chemiluminescence was detected with Image Quant LAS
4000 mini technology (GE Healthcare, Barcelona, Spain). Quantification was performed using
Image Studio Lite Software. Data were represented as protein levels relative to the control cells
(untransfected cells).
Cell titration
Before performing the co-culture experiments, we set up the number of cells to be used for
each cell line. Cell titration was carried out by increasing either the number of macrophages or
the number of cancer cells. In the case of macrophages/PC3 co-cultures, we opted to start with
80,000 PC3 cells that were cultured with an increasing number of macrophages, observing that
the best ratio was obtained with 10,000 cells (Table 1). Regarding macrophages/SKBR3 co-cul-
tures, we selected 10,000 macrophages with an increasing number of SKBR3 cells and the best
ratio was established at 1:6 (Table 2). When using macrophages/M21 co-cultures, since M21
were more resistant to the treatment, we opted for increasing the number of macrophages to
Table 1. Co-culture titration of PC3 cells with increasing number of macrophages.
Macrophages/PC3 Co-culture titration with 80,000 PC3 cells
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60,000, thus establishing a macrophages/M21 ratio of 1:1. Finally, in the macrophages/HeLa
co-cultures, the experiments were performed using the same conditions that with macro-
phages/PC3 co-cultures.
Co-culture experiments
THP-1 cells were plated in 6-well dishes and transfected with different PPRHs against PD-1.
After 24 h, transfected THP-1 cells were treated with 2 ng/mL of PMA for differentiation.
Three days after PMA treatment, the PMA-containing medium was replaced with fresh
medium and different number of cancer cells were added to the plates containing the macro-
phages, as indicated in Table 3. After 6 h, cells were transfected with different PPRHs against
PD-L1. Cell viability was assessed 4 days after the last transfection by MTT assays. The co-cul-
ture procedure is depicted in Fig 2.
MTT assays
Four days after the last transfection, 500 μg/mL of 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl-
tetrazolium Bromide (MTT) and 100 μM of sodium succinate (both from Sigma-Aldrich,
Madrid, Spain) were added to the culture medium and incubated for 2.5 h at 37˚C for the reac-
tion. After incubation, the medium was removed and the solubilization reagent (0.57% acetic
acid and 10% sodium dodecyl sulfate in DMSO) (Sigma-Aldrich, Madrid, Spain) was added.
Cell survival was measured at 570 nm in a Modulus Microplate luminometer (Turner BioSys-
tems; Promega, Madrid, Spain). Results were expressed as the percentage of cell survival rela-
tive to cells transfected with the negative control (Hp-WC).
Apoptosis assay
Apoptosis was determined by the rhodamine method: 48 h after the last transfection, rhoda-
mine 123 (final concentration 5 μg/mL) (Sigma-Aldrich, Madrid, Spain) was added for 30
min. Then, cells were collected, centrifuged at 800 x g at 4˚C for 5 min and washed once in
PBS. The pellet was resuspended in 500 μL of cold PBS and Propidium Iodide at a final con-
centration of 5 μg/mL (Sigma-Aldrich, Madrid, Spain) was added. Flow cytometry analyses
were performed in a Beckman Coulter CyAn ADP cytometer (Beckman Coulter Inc., Madrid,
Spain) and data were analyzed using the software Summit v4.3. The percentage of propidium
Table 2. Co-culture titration of macrophages with increasing number of SKBR3 cells.
Macrophages/SKBR3 Co-culture titration with 10,000 macrophages





Table 3. Number of macrophages and cancer cells plated in each co-culture experiment.
Cancer cell
line
Number of cancer cells in co-culture
experiments
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Fig 2. Schematic representation of co-culture experiments. THP-1 cells were plated and immediately transfected with PPRHs against PD-1. After 24
h, transfected THP-1 cells were differentiated to macrophages (Mϕ) with PMA for 3 days. At that time, the PMA-containing medium was replaced with
fresh medium and cancer cells were added to the dishes containing the macrophages. After 6 h, cells were transfected with different PPRHs against
PD-L1. Cell viability (MTT) assay was performed 4 days after transfection with PPRHs against PD-L1.
https://doi.org/10.1371/journal.pone.0206818.g002
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iodide-negative and rhodamine-negative cells corresponded to the apoptotic population. Data
were expressed as the apoptosis fold-increase levels relative to the co-culture transfected with
the negative control Hp-WC.
Statistical analyses
Statistical analyses were carried out using GraphPad Prism 5 (GraphPad Software, California,
USA). All data are shown as the mean ± SEM of three independent experiments. Statistical sig-
nificance was determined using one-way analysis of variance, followed by Dunnett’s multiple
comparison test. In the apoptosis experiments, a two-way ANOVA with Sidak’s multiple com-
parisons test was used. Differences were considered significant when p< 0.05.
Results
Effect of PPRHs on PD-1 and PD-L1 mRNA and protein levels
PPRHs against PD-1 were tested in THP-1 cells. PD-1 mRNA levels were determined upon
cell incubation with two different PPRHs against PD-1, HpPD1-Pr and HpPD1-E1, whose
sequences are shown in Fig 1. These PPRHs were able to decrease PD-1 mRNA levels by 2.4
and 2.7-fold, respectively, compared to the negative control Hp-WC (Fig 3A). On the other
hand, when targeting PD-L1 in PC3 cells, two different PPRHs were used, HpPDL1-I1 and
HpPDL1-I2 (Fig 1), which decreased PD-L1 mRNA levels by 2.2 and 1.8-fold, respectively,
compared to the negative control (Fig 3B). When analyzing PD-1 protein levels in THP-1 cells,
HpPD1-Pr and HpPD1-E1 decreased PD-1 protein by 78% and 66%, respectively, relative to
the control (Fig 4A). HpPDL1-I1 and HpPDL1-I2 decreased PD-L1 protein levels in PC3 cells
by 69% and 71%, respectively, compared to the control (Fig 4B).
Fig 3. Effect of PPRHs on PD-1 and PD-L1 mRNA levels. A) THP-1 cells (90,000) were transfected with two PPRHs against PD-1 and mRNA levels
were determined 48 h after transfection. B) PC3 cells (90,000) were transfected with two PPRHs against PD-L1 and mRNA levels were assessed 24 h
after transfection. mRNA levels are plotted relative to the cells treated with the negative control (Hp-WC). Data represent the mean ± SEM of three
experiments. (�p< 0.05, ��p< 0.01, ���p< 0.005).
https://doi.org/10.1371/journal.pone.0206818.g003
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Effect of PPRHs on cell viability in PC3 and THP-1 cells
We determined whether the different PPRHs against PD-1 and PD-L1 could provoke, on their
own, any cytotoxic effect in THP-1 and PC3 cells. The transfection of the different PPRHs sep-
arately and their combinations did not cause any significant effect on cell viability in either
THP-1 (Fig 5A) or macrophages (Fig 5B). However, in PC3 cells, HpPDL1-I1 and HpPDL1-I2
directed against PD-L1, provoked a decrease in cell viability of 65% and 45%, respectively, con-
firming the role of PD-L1 in tumor cell progression (Fig 5C). In contrast, PPRHs against PD-1
did not cause any effect in PC3 cells (Fig 5C).
Effect of PPRHs on PC3 cell viability in co-culture experiments
First, we tested the effect of HpPD1-Pr and HpPD1-E1 against PD-1 and HpPDL1-I1 and
HpPDL1-I2 against PD-L1 in co-culture experiments with macrophages and PC3 cells. When
silencing PD-1 in macrophages with HpPD1-Pr or HpPD1-E1, macrophages were able to kill
37% and 39% of PC3 cells, respectively (Fig 6A). When PD-L1 was silenced with HpPDL1-I1
or HpPDL1-I2 in PC3 cells, 62% and 66% of the cells were killed by macrophages (Fig 6A). To
assess whether the inhibition of both target genes could lead to an enhanced effect, macro-
phages and PC3 cells were transfected together in co-culture experiments with the four combi-
nations of PPRHs such as each of the two hairpins against PD-1 was combined with each one
Fig 4. Effect of PPRHs on PD-1 and PD-L1 protein levels. A) THP-1 cells (90,000) were transfected with two PPRHs against PD-1 and protein
extracts were obtained after 48 h. B) PC3 cells (90,000) were transfected with two PPRHs against PD-L1 and proteins were extracted after 24 h.
Representative Western blot images of PD-1 and PD-L1 are shown. The quantification of the changes in protein levels were determined upon
normalization with the signal corresponding to GAPDH protein. Non-transfected cells and cells treated with the negative control hairpin were used as
controls. Data represent the mean ± SEM of three experiments. (����p< 0.001).
https://doi.org/10.1371/journal.pone.0206818.g004
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Fig 5. Effect on cell viability upon incubation with PPRHs against PD-1 and PD-L1. A) THP-1 cells (10,000) were
treated with PPRHs against PD-1, PD-L1 or in combination. B) Macrophages (10,000) were treated with PPRHs
against PD-1, PD-L1 or in combination. C) PC3 cells (80,000) were transfected with PPRHs against PD-1 and PD-L1.
Cell viability was assessed 5 days after transfection. Cells treated with the negative control hairpin (Hp-WC) were used
as control. Data represent the mean ± SEM of three independent experiments performed on different days.
(���p<0.005, ����p< 0.001).
https://doi.org/10.1371/journal.pone.0206818.g005
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against PD-L1. In these conditions, we observed that the best combination of PPRHs against
PD-1/PD-L1 was HpPD1-Pr/HpPDL1-I1 that provoked 90% cell death in co-culture (Fig 6B).
Effect of PPRHs on cell viability in co-culture experiments with M21, HeLa
and SKBR3 cells
To extend the results observed in PC3 cells, we incubated all the combinations of PPRHs
against PD-1 and PD-L1 in three other cancer cell lines, M21, HeLa and SKBR3, in co-culture
experiments. In M21 cells, the best combination of PPRHs was HpPD1-E1/HpPDL1-I1, which
provoked 65% cell death (Fig 7A). In HeLa cells, the HpPD1-E1/HpPDL1-I1 combination led
to a reduction of 92% in cell viability (Fig 7B). Finally, the combination HpPD1-E1/HpPDL-I2
in SKBR3 cells was able to reduce cell viability by 88% (Fig 7C).
Level of apoptosis in co-culture experiments with PC3, M21, HeLa and
SKBR3 cells
To gain insight into the mechanism that provoked cancer cells death in the co-culture experi-
ments, we determined the levels of apoptosis in the different cell lines upon 48 hours of incu-
bation with the different PPRHs. The most effective combinations of PPRHs against PD-1 and
PD-L1 determined in the cell viability assays for each cancer cell line were selected for the apo-
ptosis studies. First of all, we checked the effect on apoptosis of the different combinations of
PPRHs in macrophages. We did not observe any increase in the apoptotic levels (Fig 8A), thus
demonstrating that macrophages were not affected by the transfection of the different PPRHs.
However, co-cultures of macrophages with either PC3, HeLa or SKBR3 cells showed 2.1, 2.7
Fig 6. Macrophages/PC3 co-culture experiments. A) Effect on cell viability of PPRHs against PD-1 transfected only in 10,000 macrophages or PPRHs
against PD-L1 transfected only in 80,000 PC3 cells, in co-culture experiments. B) Effect on cell viability, in co-culture experiments, of PPRHs against
PD-1 transfected in macrophages plus PPRHs against PD-L1 transfected in PC3 cells, making a total of four combinations of PPRHs. Co-cultures
incubated with the negative control hairpin (Hp-WC) were used as controls. Data represent the mean ± SEM of three independent experiments.
(����p< 0.001).
https://doi.org/10.1371/journal.pone.0206818.g006
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Fig 7. Co-culture experiments with other cancer cell lines. M21 (60,000) (A), HeLa (80,000) (B) or SKBR3 (60,000)
(C) cells were co-cultured with 60,000, 10,000 and 10,000 macrophages, respectively. Macrophages were treated with
either HpPD1-Pr or HpPD1-E1 whereas cancer cells were transfected with either HpPDL1-I1 or HpPDL1-I2 against
PD-L1. Co-cultures treated with the negative control hairpin (Hp-WC) were used as control. Data represent the
mean ± SEM of at least three experiments. (��p< 0.01, ����p< 0.001).
https://doi.org/10.1371/journal.pone.0206818.g007
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and 1.8-fold increase in apoptosis, respectively, when compared to their respective negative
controls (Fig 8B). Finally, co-culture of macrophages with M21 cancer cell line showed a mod-
erate increase (1.3-fold) in the apoptotic population after the treatment (Fig 8B), in accordance
with the observed results in cell viability.
Discussion
In this work we describe an immunotherapy approach using PPRHs directed against PD-1 and
PD-L1 in PMA-differentiated THP-1 cells and PC3 cancer cells, respectively, to favor the elim-
ination of tumor cells by macrophages. It has been previously demonstrated that these mole-
cules represent a novel gene silencing tool against different cancer targets, both in vitro [20,25–
27] and in vivo [28]. In addition, PPRHs are more stable, showing a half-life much longer than
that of siRNAs, and they do not activate the innate inflammatory response [29]. We have used
this gene silencing tool to conduct an immunotherapy approach against both CD47 in MCF-7
cells and SIRPα in macrophages, respectively, achieving a large decrease in cell viability [23].
In the present study, we showed that different cancer cells were killed by macrophages in
co-culture experiments upon silencing of PD-1/PD-L1 interaction with four different PPRHs,
whereas tumor cells remain unaffected when treated with the negative control.
A first step consisted in determining at the molecular level that the designed PPRHs were
able to decrease the expression at the level of mRNA and protein of PD-1 and PD-L1 in THP-1
monocytes and PC3 cells, respectively, thus demonstrating the specific gene silencing effect of
the four PPRHs used.
An important point was to verify whether any of the four PPRHs used in the study was able
to produce a cytotoxic effect per se due to the specific silencing of either PD-1 or PD-L1 in both
THP-1 and PC3 cells, in the absence of co-culture. The rationale for this control was to state
the contribution of macrophages in the co-culture experiments to eliminate cancer cells after
silencing PD-1 and PD-L1 in THP-1 and PC3 cells, respectively, and not by the effect that the
PPRHs could provoke by themselves. In the case of THP-1 cells and macrophages, none of the
Fig 8. Apoptosis determination. A) Apoptotic levels in macrophages treated with the different combinations of PPRHs. B)
Apoptotic levels in co-culture experiments using the most effective combination of PPRHs for each cancer cell line. Changes in
apoptosis are represented relative to co-cultures transfected with the negative control hairpin (Hp-WC). Data represent the
mean ± SEM of three experiments performed on different days. (�p< 0.05, ��p< 0.01, ���p< 0.005, ����p< 0.001).
https://doi.org/10.1371/journal.pone.0206818.g008
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four PPRHs, two against PD-1 and two against PD-L1, produced a significant effect on cell via-
bility. However, in PC3 cells, the two PPRHs directed against PD-L1 were able to decrease cell
viability by themselves. It has been reported that, aside from avoiding tumor immunity, PD-1/
PD-L1 inhibition has also cancer cell-intrinsic functions that promote tumor growth and sur-
vival such as mTOR signaling. Therefore, suppressing either PD-1 or PD-L1 could attenuate
the growth of PD-L1+ cancer cells [30,31]. In this direction, in a recent study Li et al. reported
that the inhibition of PD-L1 with a siRNA in gastric cancer cells suppressed cell proliferation,
migration and tumorigenicity both in vitro and in vivo [32]. Another study also demonstrated
that silencing PD-L1 in colon cancer cells with a siRNA reduced cell progression and led to an
increase in apoptosis [33]. Similarly, Song et al. reported that knocking down PD-L1 in pan-
creatic ductal adenocarcinoma decreased cell proliferation [34]. Finally, a recent study of
Kwak and collaborators showed that silencing of PD-L1 with a siRNA in melanoma cells pro-
voked a 25% decrease in cell viability in vitro. When the siRNA complexed with a polymeric
carrier was injected in a xenograft mouse model, tumor growth was reduced by 60% approxi-
mately [35].
Cerignoli and collaborators showed that stimulated PBMCs previously treated with an anti-
PD-1 antibody provoked a maximum cytolysis of 80% in PC3 cells later in co-culture experi-
ments [36]. In this direction, in our co-culture approach, when PD-1 was silenced in macro-
phages with non-transfected PC3 cells, the reduction in cell viability was about 40%.
When comparing the effect of silencing PD-L1 with HpPDL1-I2 in PC3 cells alone with
that produced in PC3 cells co-cultured with non-transfected macrophages, the reduction of
cell viability in the latter was 20% higher. Since PD-1/PD-L1 interaction prevents the phagocy-
tosis of tumor cells by macrophages, our hypothesis was to achieve an additional effect by
inhibiting PD1/PD-L1 interaction acting on both genes in their respective cell lines, thus
increasing the efficacy of the immunotherapeutic treatment. Therefore, an important conclu-
sion of our work is that silencing PD-1 and PD-L1 in THP-1 and PC3 cells, respectively, led to
death of the vast majority of PC3 cells (90%) by macrophages in each of the four possible com-
binations of PPRHs.
At this point, we wanted to expand our results in PC3 cells to additional cancer cell lines. In
this regard the same approach was applied in M21, HeLa and SKBR3 cancer cell lines, observ-
ing that silencing of PD-1 and PD-L1 in co-culture experiments produced a high degree of cell
mortality in all cases. HeLa cells were the most affected by the treatment, followed by SKBR3
and M21 cells. Based on data from The Human Protein Atlas (https://www.proteinatlas.org/),
both cervix and prostate tissues present a higher expression of PD-L1 compared with breast
and skin tissues. For that reason, we believe that the differences in the outcome of the treat-
ment in the different cancer cell lines could be due to the differential expression of PD-L1. Iwa-
mura et al. described that when suppressing PD-L1 expression with a siRNA in a lung
adenocarcinoma cell line, the specific lysis of tumor cells conducted by CD8+ T cells was 10%
[37]. However, in our case, when silencing PD-L1 with PPRHs in PC3 cells, macrophages were
able to kill two thirds (66%) of the cancer cell population. Juneja et al. also determined that
PD-L1 expression in murine colon adenocarcinoma MC38 cells inhibited CD8+ T cell
response and cytotoxicity against tumor cells. However, CD8+ T cells were still able to kill
tumor cells that did not express PD-L1, demonstrating its significant suppressing effect [38].
Another conclusion from our study is that apoptosis is part of the mechanism of killing in
co-culture incubations with differentiated macrophages and cancer cells treated with their
respective PPRHs targeting either PD-1 or PD-L1, in agreement with those reported in [36].
The levels of apoptosis in each cell line correlate with its observed decrease in cell viability.
There are currently two anti-PD-1 and three anti-PD-L1 antibodies approved for the treat-
ment of different types of cancer and some other molecules are still in clinical trials [39].
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Several anti-CD47 antibodies are also in Phase I clinical trials [40]. In a recent study, anti-
CD47 and anti-PD-L1 monotherapies were used against tumor mice models. Although both
treatments were able to reduce tumor size, combination of anti-CD47 and anti-PD-L1 treat-
ments showed the greatest reduction, thus increasing the survival of the animals more than
either monotherapy [19]. Therefore, CD47 and PD-L1 are good targets for immunotherapy
strategies, as we also demonstrated using PPRHs against these genes in the present work and
in [23].
In conclusion, we performed an in vitro immunotherapy approach based in silencing, by
means of PPRHs, PD-1 in macrophages and PD-L1 in different cancer cells in co-culture
experiments to inhibit their interaction, thus increasing the phagocytic potency of macro-
phages against the tumor. Therefore, this work extends the usage of PPRHs as alternative phar-
macological agents in immunotherapy against PD-1 and PD-L1.
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